Comparison of parathyroid hormone (1-34) and elcatonin in postmenopausal women with osteoporosis: An 18-month randomized, multicenter controlled trial in China

Chinese Medical Journal

Volumn 126, Issue 3, 2013, Pages 457-463

  Li, Ying ^a   Xuan, Miao ^a   Wang, Bo ^a   Yang, Jun ^a   Zhang, Hong ^a   Zhang, Xiu Zhen ^a   Guo, Xiao Hui ^b   Lü, Xiao Feng ^c   Xue, Qing Yun ^d   Yang, Gang Yi ^e   Ji, Qiu He ^f   Liu, Zhi Min ^g   Li, Cheng Jiang ^h   Wu, Tian Feng ⁱ   Sheng, Zheng Yan ^j   Li, Peng Qiu ^k   Tong, Jiu Cui ^l  

^a TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d BEIJING HOSPITAL   (China)

^e THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^f FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^g SECOND MILITARY MEDICAL UNIVERSITY   (China)

^h ZHEJIANG UNIVERSITY   (China)

ⁱ ZHEJIANG HOSPITAL   (China)

^j SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^k Sichuan Peoples' Hospital   (China)

^l Anhui Provincial Center for Clinical Evaluation of Drug   (China)

more..

Author keywords

Bone mineral density; Elcatonin; Fracture; Osteoporosis; Recombinant human parathyroid hormone

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CREATININE; ELCATONIN; PARATHYROID HORMONE[1-34]; RECOMBINANT PARATHYROID HORMONE; VITAMIN D;

ADULT; AGED; ARTICLE; BACKACHE; BONE DENSITY; BONE TURNOVER; CHINA; CLINICAL CHEMISTRY; DEATH; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FRACTURE; HEADACHE; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; INCIDENCE; INJECTION SITE DERMATITIS; LEG CRAMP; LIVER METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA AND VOMITING; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; URINALYSIS;

AGED; BONE DENSITY; CALCITONIN; CHINA; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; TREATMENT OUTCOME;

EID: 84873418366     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20121626     Document Type: Article

References (27)

1. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94: 646-650.
2. Gennari C, Agnusdei D, Camporeale A. Use of calcitonin in the treatment of bone pain associated with osteoporosis. Calcif Tissue Int 1991; 49 Suppl 2: S9-S13.
3. Gennari C. Analgesic effect of calcitonin in osteoporosis. Bone 2002; 30 (5 Suppl): S67-S70.
4. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993; 14: 690-709.
5. Pettway GJ, Meganck JA, Koh AJ, Keller ET, Goldstein SA, McCauley LK. Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone 2008; 42: 806-818.
6. Bikle DD, Sakata T, Leary C, Elalieh H, Ginzinger D, Rosen CJ, et al. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res 2002; 17: 1570-1578.
7. Demiralp B, Chen HL, Koh AJ, Keller ET, McCauley LK. Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos. Endocrinology 2002; 143: 4038-4047.
8. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, et al. Parathyroid hormone and teriparatide for thetreatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005; 26: 688-703.
9. Langdahl BL, Rajzbaum G, Jakob F, Karras D, Ljunggren O, Lems WF, et al. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 2009; 85: 484-493.
10. Ishida Y, Kawai S. Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study. Am J Med 2004; 117: 549-555.
11. Toth E, Csupor E, Meszaros S, Ferencz V, Nemeth L, McCloskey EV, et al. The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures--an open label study. Bone 2005; 36: 47-51.
12. Chihara K, Iwasaki J, Iwasaki Y, Minamitani N, Kaji H, Fujita T. Central nervous system effect of calcitonin: stimulation of prolactin release in rats. Brain Res 1982; 248: 331-339.
13. Boonen S, Marin F, Obermayer-Pietsch B, Simoes ME, Barker C, Glass EV, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008; 93: 852-860.
14. Hwang JS, Tu ST, Yang TS, Chen JF, Wang CJ, Tsai KS. Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int 2006; 17: 373-378.
15. Finkelstein JS, Wyland JJ, Leder BZ, Burnett-Bowie SM, Lee H, Juppner H, et al. Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab 2009; 94: 2495-2501.
16. Crandall C. Parathyroid hormone for treatment of osteoporosis. Arch Intern Med 2002; 162: 2297-2309.
17. Nishida S, Yamaguchi A, Tanizawa T, Endo N, Mashiba T, Uchiyama Y, et al. Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone 1994; 15: 717-723.
18. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999; 104: 439-446.
19. Yu EW, Neer RM, Lee H, Wyland JJ, de la Paz AV, Davis MC, et al. Time-dependent changes in skeletal response to teriparatide: escalating vs. constant dose teriparatide (PTH 1-34) in osteoporotic women. Bone 2011; 48: 713-719.
20. Colpan L, Gur A, Cevik R, Nas K, Sarac AJ. The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis. Maturitas 2005; 51: 246-253.
21. Yoh K, Tanaka K, Ishikawa A, Ishibashi T, Uchino Y, Sato Y, et al. Health-related quality of life (HRQOL) in Japanese osteoporotic patients and its improvement by elcatonin treatment. J Bone Miner Metab 2005; 23: 167-173.
22. Avioli LV. Osteoporosis syndromes: patient selection for calcitonin therapy. Geriatrics 1992; 47: 58, 61-64, 67.
23. Fischer JA, Tobler PH, Kaufmann M, Born W, Henke H, Cooper PE, et al. Calcitonin: regional distribution of the hormone and its binding sites in the human brain and pituitary. Proc Natl Acad Sci U S A 1981; 78: 7801-7805.
24. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441.
25. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349: 1207-1215.
26. Nakajima A, Shimoji N, Shiomi K, Shimizu S, Moriya H, Einhorn TA, et al. Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J Bone Miner Res 2002; 17: 2038-2047.
27. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87: 4528-4535.